Table 3 Statement from the US Centers for Disease Control and Prevention/American Heart Association (CDC/AHA) on the measurement of C‐reactive protein, 20033.
| 1. hsCRP assay is the assay of choice and should be performed in metabolically stable persons without obvious inflammatory or infectious diseases |
| 2. The results should be expressed in mg/litre and two assays, averaged, fasting or non‐fasting, 2 weeks apart (in this way, they represent the inflammatory status better) |
| 3. The adult population should be stratified in three tertiles, at different cardiovascular risk |
| 4. Subjects at the highest tertile have about a twofold increased risk of future cardiovascular disease compared with those in the lower tertile |
| 5. Subjects with moderate risk (10–20% risk of CHD over 10 years) may benefit from measurement of CRP in addition to traditional cardiovascular risk factors |
CHD, coronary heart disease; hsCRP: high sensitivity C‐reactive protein.